Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.43 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.39 |
| ▸ | WDR5 | P61964 | 3/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
| ▸ | CFTR | P13569 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | SCN8A | Q9UQD0 | 2/20 | 0.34 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.34 |
| ▸ | BTK | Q06187 | 2/20 | 0.34 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1542476 | 0.90 | CYP3A4 (0.44) | CYP3A4CD274ABL1CFTRSCN8A | |
| SCHEMBL2127468 | 0.89 | CYP3A4 (0.44) | CYP3A4CD274JAK2 | |
| SCHEMBL2128872 | 0.86 | CYP3A4 (0.57) | CYP3A4CD274JAK2CRBNABL1 | |
| SCHEMBL1542748 | 0.86 | CYP3A4 (0.47) | CYP3A4CD274ABL1BTK | |
| SCHEMBL1543054 | 0.82 | CYP3A4 (0.44) | CYP3A4CD274ABL1CFTRSCN8A | |
| SCHEMBL1542928 | 0.82 | CYP3A4 (0.44) | CYP3A4CD274JAK2ABL1BTK | |
| SCHEMBL1542657 | 0.81 | CYP3A4 (0.49) | CYP3A4ABL1BTK | |
| SCHEMBL1543460 | 0.80 | CYP3A4 (0.44) | CYP3A4CD274ABL1BTK | |
| SCHEMBL1542627 | 0.79 | CYP3A4 (0.44) | CYP3A4CD274ABL1BTK | |
| SCHEMBL2127612 | 0.78 | CYP3A4 (0.58) | CYP3A4CD274CRBNABL1CFTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8273773-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2012-09-25 | — | — | US | claimed |
| EP-2307372-B1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2012-04-25 | — | — | EP | claimed |
| EP-2307372-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2011-04-13 | — | — | EP | claimed |
| WO-2010010017-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-01-28 | — | — | WO | claimed |
| US-20100021423-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2010-01-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100021423-A1 | Heterocyclic antiviral compounds | POLR2A, RRM2B, RRP1B | CYP3A4 528/4885CD274 3357/4885WDR5 1560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.